Checkpoint inhibitors are antibodies that target cytotoxic T lymphocyte Antigen 4 (CTLA-4), PD-1, and programmed death ligand-1 (PD-L1) and thereby block the inhibition of the immune response by the tumor and its microenvironment. This evidence concerns the gene CD274 and neoplasm.